

MDB – Pubblicazioni

Elenco delle pubblicazioni (AGGIORNATO A DICEMBRE 2018)

- sulle basi scientifiche del Metodo Di Bella
- sulle conferme cliniche mediante studi , osservazionali retrospettivi e case reports :

1)[Perspectives in pineal functions.- Di Bella L, Rossi MT, Scalera G. –Prog. Brain Res. 1979;52:475-8.](#)

2)[The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer Dr. Giuseppe Di Bella](#)  
Translational Biomedicine

3)[Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings.](#)Di Bella G, Gualano L, Di Bella L.Neuro Endocrinol Lett. 2017 Dec;**38**(7):465-474.

4)[Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast.](#)Di Bella G, Colori B, Toscano R.Neuro Endocrinol Lett. 2017 Dec;**38**(6):401-407.

5)[Congenital fibrosarcoma in complete remission with Somatostatin, Bromocriptine, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow up.](#)Di Bella G, Toscano R, Ricchi A, Colori B.Neuro Endocrinol Lett. 2015;**36**(8):725-33.

6)[Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy.](#)

Di Bella L, Di Bella G.Neuro Endocrinol Lett. 2015 Dec;**36**(7):661-76.

7)[Recurrent Glioblastoma Multiforme \(grade IV - WHO 2007\): a case of complete objective response - concomitant administration of Somatostatin / Octreotide, Retinoids, Vit E, Vit D3, Vit C, Melatonin, D2 R agonists \(Di Bella Method.](#)Di Bella G, Leci J, Ricchi A, Toscano R.Neuro Endocrinol Lett. 2015;**36**(2):127-32.

8)[Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report.](#)Di Bella G, Mascia F, Ricchi A, Colori B.

Neuro Endocrinol Lett. 2013;**34**(7):660-8.

9)[The Di Bella Method \(DBM\) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature.](#)

Di Bella G, Mascia F, Colori B.Neuro Endocrinol Lett. 2013;**34**(6):523-8. Review.

10)[The Di Bella Method \(DBM\) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of lymphomas.](#)

Di Bella G, Colori B, Mascia F. Neuro Endocrinol Lett. 2012;33(8):773-81.

11)[Melatonin anticancer effects: review.](#) Di Bella G, Mascia F, Gualano L, Di Bella L.

Int J Mol Sci. 2013 Jan 24;14(2):2410-30. doi: 10.3390/ijms14022410.

12)[The Di Bella Method \(DBM\) improved survival, objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck.](#)

Di Bella G, Colori B. Neuro Endocrinol Lett. 2012;33(3):249-56.

13)[Laudatio for centenary of the birth of Luigi Di Bella, MD, PhD.](#) Di Bella G, Di Bella A, Gualano L. Neuro Endocrinol Lett. 2012;33(3):247-8.

14)[The Di Bella Method \(DBM\) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer.](#)

Di Bella G. Neuro Endocrinol Lett. 2011;32(6):751-62.

15)[The Di Bella Method \(DBM\).](#) Di Bella G. Neuro Endocrinol Lett. 2010;31 Suppl 1:1-42. Review.

16)[Complete objective response of neuroblastoma to biological treatment.](#)

Di Bella G, Colori B. Neuro Endocrinol Lett. 2009;30(4):437-49.

17)[Complete objective response of oesophageal squamocellular carcinoma to biological treatment.](#) Di Bella G, Madarena M. Neuro Endocrinol Lett. 2009;30(3):312-21.

18)[Complete objective response to biological therapy of plurifocal breast carcinoma.](#)

Di Bella G. Neuro Endocrinol Lett. 2008 Dec;29(6):857-66.

19) [Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status.](#) Norsa A, Martino V. *Cancer Biother Radiopharm.* 2007 Feb;22(1):50-5.

20) [Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status.](#)

Norsa A, Martino V. *Cancer Biother Radiopharm.* 2006 Feb;21(1):68-73.

21) [Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial.](#) Todisco M1, Casaccia P, Rossi N. *Cancer Biother Radiopharm.* 2001 Apr;16(2):171-7.

22) [Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH.](#) Todisco M. *Cancer Biother Radiopharm.* 2009 Jun;24(3):353-5.

23) [Key aspects of melatonin physiology: thirty years of research.](#) Di Bella L, Gualano L. *Neuro Endocrinol Lett.* 2006 Aug;27(4):425-32. Review.

24) [Melatonin effects on megakaryocyte membrane patch-clamp outward K<sup>+</sup> current.](#) Di Bella L, Bruschi C, Gualano L. *Med Sci Monit.* 2002 Dec;8(12):BR527-31.

25) Di Bella G, Colori B, Scanferlato R. [The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature.](#) *Neuro Endocrinol Lett.* 2018 Sep;39(3):179-188. PubMed PMID: 30431745.

26) Di Bella G, Scanferlato R, Colori B (2018) [Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor.](#) *Transl Biomed.* Vol.9 No.3:151

27) Di Bella G, Colori B, Scanferlato R (2018) [The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer.](#) *Transl Biomed.* Vol.9 No.1:146